VXRT News and Press, Vaxart Inc. From 04/28/23

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2023 after the market close on Thurs...

2023-04-24 05:30:00 ET Some companies offer you plenty of earnings visibility -- even if their shares slip in the near term, you're pretty confident they'll gain over time. You'll want a lot of these stocks in your portfolio. But if you're comfortable with risk, you may want to add another ...

2023-03-31 15:00:41 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calenda...

SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will make presentations at the World Vaccine Congress Washington 2023 in Washin...

Company to provide a detailed overview of its norovirus clinical program Webcast to be held on March 28, 2023 at 1:00 p.m. ET SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will host a key opinion leader video webcast...

2023-03-15 20:51:01 ET Vaxart, Inc. (VXRT) Q4 2022 Earnings Conference Call March 15, 2023 04:30 PM ET Company Participants Brant Biehn - Senior Vice President, Business Operations Andrei Floroiu - Chief Executive Officer James Cummings - Chief Medical Officer ...

2023-03-15 16:33:16 ET Issuing its Q4 2022 financials on Wednesday, vaccine developer Vaxart ( NASDAQ: VXRT ) announced a portfolio reorganization to prioritize its oral norovirus vaccine program and postpone further COVID-19 clinical trials. The decision, which also inv...

2023-03-15 16:02:16 ET Vaxart press release ( NASDAQ: VXRT ): FY GAAP EPS of -$0.84 misses by $0.01 . Vaxart ended the year with cash, cash equivalents, restricted cash and marketable securities of $95.7 million. Vaxart expects its cash on hand will extend into Q2 ...

Prioritizing oral bivalent norovirus candidate, one of the most advanced norovirus vaccines in development Will continue preclinical development of novel COVID-19 vaccine constructs to enhance cross-reactivity and potency with the goal of developing a pan-betacoronavirus vaccine ...

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2022 after the market close on Wednes...